Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.51 |
| ▸ | BTK | Q06187 | 6/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008652 | 1.00 | PIK3CD (0.51) | PIK3CDBTKGPR119PIK3CAPIK3CB | |
| SCHEMBL16008651 | 1.00 | PIK3CD (0.51) | PIK3CDBTKGPR119PIK3CAPIK3CB | |
| SCHEMBL30633869 | 1.00 | PIK3CD (0.51) | PIK3CDBTKGPR119PIK3CAPIK3CB | |
| SCHEMBL16008125 | 0.88 | GPR119 (0.46) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008508 | 0.88 | GPR119 (0.46) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008511 | 0.88 | GPR119 (0.46) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008126 | 0.88 | GPR119 (0.46) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008882 | 0.86 | PIK3CD (0.49) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008885 | 0.86 | PIK3CD (0.49) | PIK3CDGPR119PIK3CAPIK3CBPIK3CG | |
| SCHEMBL16008553 | 0.86 | BTK (0.50) | PIK3CDBTKPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786608-B2 | Isoquinolinyl triazolone complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11786608-B2 | Isoquinolinyl triazolone complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11786608-B2 | Isoquinolinyl triazolone complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| CN-109071496-B | Isoquinolinyl triazolone complexes | 武田药品有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-3436447-B1 | ISOQUINOLINYL TRIAZOLONE COMPLEXES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-20210138086-A1 | ISOQUINOLINYL TRIAZOLONE COMPLEXES | CHEN RONGLIANG (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210138086-A1 | ISOQUINOLINYL TRIAZOLONE COMPLEXES | CHEN RONGLIANG (US) | 2021-05-13 | — | — | US | disclosed |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA INC. | 2016-10-27 | — | — | US | disclosed |
| US-9402841-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9402841-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9402841-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| WO-2014164558-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | PIK3CD 52/4885BTK 1/4885GPR119 3246/4885 |
| US-11786608-B2 | Isoquinolinyl triazolone complexes | BTK, LCK, SYK | PIK3CD 35/4885BTK 1/4885GPR119 2444/4885 |
| US-20210138086-A1 | ISOQUINOLINYL TRIAZOLONE COMPLEXES | BTK, LCK, SYK | PIK3CD 35/4885BTK 1/4885GPR119 2444/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | PIK3CD 52/4885BTK 1/4885GPR119 3246/4885 |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | PIK3CD 52/4885BTK 1/4885GPR119 3246/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | PIK3CD 52/4885BTK 1/4885GPR119 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.